JessicaE(Ravikoff)AllegrettiMD
Gastroenterology • Boston, MAAssociate Director, Crohn’s and Colitis Center
Dr. Allegretti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
# Brigham
Boston, MA 02115Phone+1 617-732-6389
Summary
- Dr. Jessica Allegretti is a gastroenterologist in Boston, MA and is affiliated with Brigham and Women's Hospital. She received her medical degree from University of Miami Leonard M. Miller School of Medicine and has been in practice 8 years. She is experienced in inflammatory bowel disease.
Education & Training
Brigham and Women's HospitalFellowship, Gastroenterology, 2012 - 2015
Massachusetts General HospitalResidency, Internal Medicine, 2009 - 2012
University of Miami Leonard M. Miller School of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2011 - 2026
NH State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
CT State Medical License 2022 - 2024
Publications & Presentations
PubMed
- 231 citationsStrain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation.Christopher Smillie, Jenny Sauk, Dirk Gevers, Jonathan Friedman, Jaeyun Sung
Cell Host & Microbe. 2018-02-14 - 196 citationsThe evolution of the use of faecal microbiota transplantation and emerging therapeutic indicationsJessica R. Allegretti, Benjamin H. Mullish, Colleen R. Kelly, Monika Fischer
Lancet. 2019-08-03 - 59 citationsPredictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.Jessica R. Allegretti, Edward L. Barnes, Betsey Stevens, Margaret Storm, Ashwin N. Ananthakrishnan
Digestive Diseases and Sciences. 2017-03-29
Press Mentions
Four Analyses of Data for REBYOTA™ (Fecal Microbiota, Live – Jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. Difficile Infection, Presented at DDW 2023May 8th, 2023- FMT Tops Standard of Care for First or Second C. Diff InfectionsSeptember 29th, 2022
- Opinion: Splashing Cold Water on Poop Transplants for Weight LossSeptember 1st, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
